Insider Sell: Ptc Therapeutics
9:08AM ET 8/12/2022 MT NewswiresStephanie Okey, Director, on August 09, 2022, sold 2,296 shares in Ptc Therapeutics (PTCT) for $118,522. Following the Form 4 filing with the SEC, Okey has...
Quotes Snapshot > PTCT
PTC Therapeutics Inc PTCT:NASDAQ
Last Price$51.45NASDAQ Closing Price as of 4:00PM ET 8/19/22
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change-0.65(1.25%)
Bid (Size)$47.12 (31)
Ask (Size)$55.19 (3)
Day Low / High$51.08 - 52.14
Volume314.5 K
Read more news Recent News
--Raymond James Adjusts PTC Therapeutics' Price Target to $60 From $55, Keeps Outperform Rating
10:28AM ET 8/11/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
--Credit Suisse Lifts PTC Therapeutics' Price Target to $55 from $52, Keeps Neutral Rating
10:37AM ET 8/05/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
--RBC Raises Price Target on PTC Therapeutics to $49 From $46, Maintains Sector Perform Rating
8:17AM ET 8/05/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
View all Commentary and Analysis
ClearPoint Neuro: Picks & Shovels Galore
5:11PM ET 8/19/2022 Seeking AlphaPTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz On Q2 2022 Results - Earnings Call Transcript
8:02AM ET 8/07/2022 Seeking AlphaPTC Therapeutics Investor Presentation - Slideshow
9:04AM ET 7/25/2022 Seeking AlphaPTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price
5:26PM ET 6/24/2022 Seeking AlphaCompany Profile
Business DescriptionPTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The firm's portfolio includes Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ. View company web site for more details
| Address | 100 Corporate Court South Plainfield, New Jersey 07080-2449 |
| Phone | +1.908.222.7000 |
| Number of Employees | 517 |
| Recent SEC Filing | 08/15/2022 8-K |
| Chief Executive Officer & Director | Stuart Walter Peltz |
| Chief Operating Officer | Matthew B. Klein |
| Chief Financial Officer | Emily Hill |
| Chief Technical Operations Officer | Neil Gregory Almstead |
Company Highlights
| Price Open | $51.57 |
| Previous Close | $52.10 |
| 52 Week Range | $25.01 - 54.46 |
| Market Capitalization | $3.7 B |
| Shares Outstanding | 71.5 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 10/27/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$7.99 |
| Beta vs. S&P 500 | N/A |
| Revenue | $264.7 M |
| Net Profit Margin | -89.89% |
| Return on Equity | 1,335.54% |
Analyst Ratings as of 03/01/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |